Novartis: Ovarian cancer drug disappoints in trial - BusinessWeek

[INCIID News Feed]

<img alt="" height="1" width="1" />
Novartis: Ovarian cancer drug disappoints in trial
BusinessWeek
Swiss drug maker Novartis AG said Thursday it won&#39;t ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing. The drug, patupilone, failed to show improvements over existing drugs in 829 patients ...
Novartis&#39;s Patupilone Fails In Ovarian Cancer TrialWall Street Journal
Pharma News: Pfizer, NovartisMarketNewsVideo.com
Novartis&#39;s patupilone fails in ovarian cancer trialReuters
RTT News -eMaxHealth -MarketWatch
all 28 news articles &raquo;


More...